Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele

(2013) Travis J. O'Brien et al.   CLINICA CHIMICA ACTA

Transporter Studies in Drug Development: Experience to Date and Follow-Up on Decision Trees From the International Transporter Consortium

(2013) D Tweedie et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

(2013) Drosos E. Karageorgopoulos et al.   CURRENT OPINION IN INFECTIOUS DISEASES

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

(2013) D Alan Herbst et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C

(2013) Nihar Shah et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

(2013) Stefan Zeuzem et al.   GASTROENTEROLOGY

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

(2013) Maria Buti et al.   GASTROENTEROLOGY

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir

(2013) Xiao Tong et al.   JOURNAL OF INFECTIOUS DISEASES

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

(2013) E. J. Lawitz et al.   JOURNAL OF VIRAL HEPATITIS

Drug–drug interactions during antiviral therapy for chronic hepatitis C

(2013) Jennifer J. Kiser et al.   Nature Reviews Gastroenterology & Hepatology

In vitroOATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

(2013) William J. Chiou et al.   XENOBIOTICA

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells

(2012) Miki Nagai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters

(2012) Annett Kunze et al.   BIOCHEMICAL PHARMACOLOGY

Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions

(2012) Gian Camenisch et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

(2012) Yoshihisa Shitara et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1- and OATP1B3-mediated Uptake

(2012) Yoshihisa Shitara et al.   Drug Metabolism and Pharmacokinetics

Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response

(2012) Inna Y. Gong et al.   Drug Metabolism and Pharmacokinetics

Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins

(2012) Pradeep Sharma et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

(2012) Evita van de Steeg et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

(2012) David Burger et al.   JOURNAL OF HEPATOLOGY

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

(2011) Jee Eun Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition

(2011) L. B. Ramsey et al.   GENOME RESEARCH

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

(2011) Varun Garg et al.   HEPATOLOGY

Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin

(2011) Varun Garg et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

(2010) Ruben C. Hartkoorn et al.   Pharmacogenetics and Genomics

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The impact ofSLCO1B1polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men

(2009) Fabiana B. Kohlrausch et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy

(2009) Tomomi Furihata et al.   PHARMACOGENOMICS JOURNAL

Viral hepatitis and HIV coinfection

(2007) Mark S. Sulkowski   JOURNAL OF HEPATOLOGY